1Myeloma Trialists' Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27randomized trials[J].J Clin Oncol,1998,16(12):3832-3842.
2Clerc D,Fermand J P,Mariette X.Treatment of multiple myeloma[J].Joint Bone Spine,2003,70(3):175-186.
3Turesson I,Abildgaard N,Ahlgren T,et al.Prognostic evaluation in multiple myeloma:an analysis of the impact of new prognostic factors[J].Br J Haematol,1999,106(4):1005-1012.
4Bataille R,Boccadoro M,Klein B,et al.C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system[J].Blood,1992,80 (3):733-737.
5Greipp P R,San Miguel J,Durie B G,et al.International staging system for multiple myeloma[J].J Clin Oncol,2005,23 (15):3412-3420.
6Pruzanski W.Clinical manifestations of multiple myeloma:relation to class and type M component[J].Can Med Assoc J,1976,114(10):896-897.
7Jacobson J L,Hussein M A,Barlogie B,et al.A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience[J].BrJ Haematol,2003,122(3):441-450.
8Bataille R,Durie B G,Grenier J,et al.Prognostic factors and staging in multiple myeloma:a reappraisal[J].J Clin Oncol,1986,4(1):80-87.
7Greipp PR,Raymond NM,Kyle RA. Mutiple myeloma significance of plasmablastic subtype in morphological classification[J].Blood,1985,(02):305-310.
8康格非.临床生物化学和生物化学检验[M]北京:人民卫生出版社,199814-15.
9Bouafia F,Drai J,Bienvenu J. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies[J].Bulletin Du Cancer,2004,(7/8):229-240.
